🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareNovo Nordisk CagriSema Phase 3 results — need advice Page 6

Novo Nordisk CagriSema Phase 3 results — need advice

mike_mod Tue, Nov 18, 2025 at 8:31 PM 43 replies 1,982 viewsPage 6 of 9
BenResearch_OR
Senior Member
2,456
11,234
Dec 2023
Oregon
Nov 26, 2025 at 11:17 AM#26
NicoleRaleigh said:
If you are going to change something, change one thing and give it long enough to express itself.

This is exactly what I could not find anywhere else.

19 19julia.endo, JessicaM_2024, TomFromTexas and 16 others
Reply Quote Save Share Report
rachel_ABQ
Member
178
890
Dec 2024
Albuquerque, NM
Nov 27, 2025 at 9:00 AM#27

Adding the clinical framing, because it changes how the question reads. The distinction that resolves most of these threads is between what is true on average and what is true for one person. Both are real; they answer different questions and get quoted as if they were the same one.

18 18DadBodDave, AmyNC_wife, SkepticalSean and 15 others
Reply Quote Save Share Report
wendy_avl
Member
245
1,123
Oct 2024
Asheville, NC
Nov 28, 2025 at 6:43 AM#28
rachel_ABQ said:
The distinction that resolves most of these threads is between what is true on average and what is true for one person.

Can confirm. Same sequence, different timescale. I had assumed I was the exception until I read this.

17 17TomTeleRx, DoseLogDan, SleepFixSam and 14 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
tom_AK
New Member
28
112
Jan 2026
Anchorage, AK
Nov 29, 2025 at 4:27 AM#29
rachel_ABQ said:
The distinction that resolves most of these threads is between what is true on average and what is true for one person.

There is a second half to this that has not been said yet. Relative and absolute effects need reading together. A 20% relative reduction on a high baseline risk is a large absolute benefit; the same relative figure on a low baseline risk is a small one, and press summaries almost always quote the relative number because it is bigger.

16 16jennifer_SEA, tyler_CSCS, VanRx_Mike and 13 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Nov 30, 2025 at 2:11 AM#30

Reporting back.

Follow-up: I read the paper rather than the summary and the qualifier I was missing was in the second paragraph of the results.

44 19PurityPaulOR, MaxMetOK, MounjBrad and 41 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register